Delcath Systems (NASDAQ:DCTH) Upgraded at Wall Street Zen

Key Points

• Analyst sentiment improved: Wall Street Zen and Zacks Research upgraded Delcath Systems to “strong buy.” The consensus rating is “Buy,” with an average price target of $29.33.
• Delcath reported quarterly EPS of $0.17, beating the estimate of a $0.09 loss, while revenue of $35.1 million exceeded expectations of $26.0 million.
• Director Bridget A. Martell sold 22,500 shares for about $488,475, reducing her stake by 50%.

Delcath Systems (NASDAQ:DCTH - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday, Wall Street Zen reports.

Other research analysts have also issued research reports about the company. Weiss Ratings raised Delcath Systems from a "hold (c-)" rating to a "hold (c+)" rating in a research report on Thursday. HC Wainwright raised their target price on Delcath Systems from $32.00 to $36.00 and gave the company a "buy" rating in a research note on Tuesday. BTIG Research lifted their price target on Delcath Systems from $21.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, November 9th. Finally, Zacks Research upgraded Delcath Systems from a "hold" rating to a "strong-buy" rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Delcath Systems presently has a consensus rating of "Buy" and an average price target of $29.33.

Delcath Systems Price Performance

Shares of NASDAQ DCTH opened at $20.55 on Friday. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $22.51. The stock has a market capitalization of $714.93 million, a P/E ratio of 128.44 and a beta of 0.62. The company's 50-day moving average is $15.88 and its 200 day moving average is $12.70.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.26. The business had revenue of $35.10 million during the quarter, compared to analyst estimates of $25.99 million. Delcath Systems had a net margin of 6.05% and a return on equity of 5.56%. Research analysts anticipate that Delcath Systems will post 0.13 earnings per share for the current year.

Insider Activity at Delcath Systems

In related news, Director Bridget A. Martell sold 22,500 shares of the stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $21.71, for a total transaction of $488,475.00. Following the sale, the director directly owned 22,500 shares of the company's stock, valued at approximately $488,475. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 19.36% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP increased its holdings in Delcath Systems by 69.8% in the 3rd quarter. Marshall Wace LLP now owns 371,893 shares of the company's stock worth $5,939,000 after acquiring an additional 152,930 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Delcath Systems during the second quarter valued at approximately $1,362,000. Allspring Global Investments Holdings LLC purchased a new position in Delcath Systems during the first quarter valued at approximately $306,000. Kopp Family Office LLC bought a new position in shares of Delcath Systems in the third quarter worth approximately $450,000. Finally, Sei Investments Co. boosted its position in shares of Delcath Systems by 100.0% in the first quarter. Sei Investments Co. now owns 44,058 shares of the company's stock worth $409,000 after purchasing an additional 22,029 shares during the period. 61.12% of the stock is currently owned by institutional investors.

Key Stories Impacting Delcath Systems

Investors following DCTH have been watching these stories:

• Positive Sentiment: Zacks Research upgraded DCTH from “hold” to “strong-buy.” Zacks also cited the stock’s recent price strength and momentum, while noting that estimate revisions may support the trend. Zacks price-strength article
• Neutral Sentiment: Delcath will be featured on “Health Uncensored with Dr. Drew” in a segment about liver-directed cancer treatment. The coverage may raise awareness, but no direct commercial or financial impact was disclosed. BioSpace announcement
• Negative Sentiment: Director Bridget A. Martell sold 22,500 shares for about $488,475, cutting her stake by 50%. Insider sales can raise concern, though the filing does not state the reason for the transaction. SEC Form 4

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver's blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company's HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.